JP2018198596A5 - - Google Patents

Download PDF

Info

Publication number
JP2018198596A5
JP2018198596A5 JP2018128111A JP2018128111A JP2018198596A5 JP 2018198596 A5 JP2018198596 A5 JP 2018198596A5 JP 2018128111 A JP2018128111 A JP 2018128111A JP 2018128111 A JP2018128111 A JP 2018128111A JP 2018198596 A5 JP2018198596 A5 JP 2018198596A5
Authority
JP
Japan
Prior art keywords
pad4
antibody according
antibody
seq
pad4 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018128111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018198596A (ja
JP6675739B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018198596A publication Critical patent/JP2018198596A/ja
Publication of JP2018198596A5 publication Critical patent/JP2018198596A5/ja
Application granted granted Critical
Publication of JP6675739B2 publication Critical patent/JP6675739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018128111A 2015-03-06 2018-07-05 新規抗pad4抗体 Active JP6675739B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015044518 2015-03-06
JP2015044518 2015-03-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017505334A Division JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体

Publications (3)

Publication Number Publication Date
JP2018198596A JP2018198596A (ja) 2018-12-20
JP2018198596A5 true JP2018198596A5 (cg-RX-API-DMAC7.html) 2019-04-18
JP6675739B2 JP6675739B2 (ja) 2020-04-01

Family

ID=56880525

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017505334A Active JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体
JP2018128111A Active JP6675739B2 (ja) 2015-03-06 2018-07-05 新規抗pad4抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017505334A Active JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体

Country Status (5)

Country Link
US (2) US11447569B2 (cg-RX-API-DMAC7.html)
EP (2) EP4223786A3 (cg-RX-API-DMAC7.html)
JP (2) JP6369922B2 (cg-RX-API-DMAC7.html)
ES (1) ES2952132T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016143753A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223786A3 (en) 2015-03-06 2023-08-16 Public University Corporation Yokohama City University Novel anti-pad4 antibodies
EP4170029A3 (en) 2017-09-19 2023-08-30 Tropic Biosciences UK Limited Modifying the specifity of plant non-coding rna molecules for silencing gene expression
WO2019131769A1 (ja) * 2017-12-26 2019-07-04 公立大学法人名古屋市立大学 新規抗pad4抗体
WO2020168024A1 (en) * 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
JP7570338B2 (ja) 2019-02-15 2024-10-21 インテグラル・モレキュラー・インコーポレイテッド クローディン6抗体及びその使用
CN111733151B (zh) * 2020-07-13 2021-11-12 山东新创生物科技有限公司 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用
CN116323673A (zh) * 2020-08-10 2023-06-23 整体分子公司 用于制备抗体文库和从其分离的抗体的方法和组合物
AR124914A1 (es) * 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
CA3215997A1 (en) * 2021-04-21 2022-10-27 Connor SWEENEY Method and composition
KR20250040994A (ko) * 2022-07-22 2025-03-25 브리스톨-마이어스 스큅 컴퍼니 인간 pad4에 결합하는 항체 및 그의 용도
IL319951A (en) 2022-11-30 2025-05-01 Integral Molecular Inc Antibodies targeting claudin 6, including its bispecific formats
AR131398A1 (es) 2022-12-19 2025-03-12 Astrazeneca Ab Tratamiento de enfermedades autoinmunitarias
WO2024233254A2 (en) * 2023-05-05 2024-11-14 The Johns Hopkins University Human monoclonal antibodies for treating subjects suffering from pulmonary fibrosis
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025122927A1 (en) * 2023-12-06 2025-06-12 Integral Molecular, Inc. Antibodies directed to claudin 18.2, including bispecific formats thereof
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4304274B2 (ja) 2004-03-04 2009-07-29 国立大学法人広島大学 ニワトリ−ヒトキメラ抗体発現用ベクターおよびこれを用いたニワトリ−ヒトキメラ抗体生産方法、並びにその利用
WO2005085438A1 (ja) 2004-03-09 2005-09-15 Nagoya Industrial Science Research Institute ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
JP5252339B2 (ja) * 2007-12-25 2013-07-31 地方独立行政法人東京都健康長寿医療センター Pad4及び抗pad4抗体の測定方法並びに関節リウマチの検出方法
US20130101611A1 (en) * 2009-11-25 2013-04-25 The Johns Hopkins University Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity
WO2012026309A1 (ja) 2010-08-23 2012-03-01 公立大学法人横浜市立大学 抗pad4抗体医薬の創成
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
EP4223786A3 (en) 2015-03-06 2023-08-16 Public University Corporation Yokohama City University Novel anti-pad4 antibodies
WO2016155745A1 (en) * 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies

Similar Documents

Publication Publication Date Title
JP2018198596A5 (cg-RX-API-DMAC7.html)
JP2017160222A5 (cg-RX-API-DMAC7.html)
JP2017113019A5 (cg-RX-API-DMAC7.html)
JP2018193386A5 (cg-RX-API-DMAC7.html)
JP2012526542A5 (cg-RX-API-DMAC7.html)
NZ600348A (en) Anti-c5a binding moieties with high blocking activity
RU2019118359A (ru) Антитело к cd73 человека
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JP2014221758A5 (cg-RX-API-DMAC7.html)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP2016020389A5 (cg-RX-API-DMAC7.html)
JP2014518883A5 (cg-RX-API-DMAC7.html)
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
JP2019531093A5 (cg-RX-API-DMAC7.html)
JP2012000112A5 (cg-RX-API-DMAC7.html)
JP2010516708A5 (cg-RX-API-DMAC7.html)
HRP20230078T1 (hr) Sredstva za vezivanje vegf/dll4 i njihova uporaba
JP2005120106A5 (cg-RX-API-DMAC7.html)
JP2015525208A5 (cg-RX-API-DMAC7.html)
JP2008525033A5 (cg-RX-API-DMAC7.html)
JP2012116856A5 (cg-RX-API-DMAC7.html)
JP2013539454A5 (cg-RX-API-DMAC7.html)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
JP2021502984A5 (cg-RX-API-DMAC7.html)
JP2016508503A5 (cg-RX-API-DMAC7.html)